icon-folder.gif   Conference Reports for NATAP  
 
  EASL 47th Annual Meeting
April 18th - 22nd 2012
Barcelona, Spain
Back grey_arrow_rt.gif
 
 
 
GS-7977 400 mg QD Safety and Tolerability in the Over 500 Patients Treated for at Least 12 Weeks
 
 
  Reported by Jules Levin EASL 2012 Apr 18-22 Barcelona Spain
 
I. Jacobson1, E. Lawitz2, J. Lalezari3, I. Crespo4, M. Davis5, T. Hassanein6, M. DeMicco7, S. Arora8, N, Gitlin9, R. Herring10, D.R. Nelson11, J.K. Anderson12, R.H. Hyland12, R.G. Hindes12, E. Albanis12, W.T. Symonds12, M.M. Berrey13 1Weill Cornell Medical College, New York, NY; 2Alamo Medical Research, San Antonio, TX; 3Quest Clinical Research, San Francisco, CA; 4Advanced Research Institute, Trinity, FL; 5South Florida Center of Gastroenterology, Wellington, FL; 6Southern California Liver Center, Coronado CA; 7Advanced Clinical Research Institute, Anaheim, CA; 8University of New Mexico Health Science Center, Albuquerque, NM; 9Atlanta Gastroenterology Associates, Atlanta, GA; 10Nashville Gastrointestinal Specialists, Nashville, TN; 11University of Florida, Gainesville, FL; 12Gilead Sciences, Inc., Foster City, CA 13 Pharmasset, Inc., Princeton, NJ, USA

EASL1.gif

EASL2.gif

EASL3.gif

EASL4.gif

EASL5.gif

EASL6.gif

EASL7.gif

EASL8.gif

EASL9.gif